Capecitabine in Women With Operable Breast Cancer

Phase 2 Terminated 80 enrolled Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center · collab Brigham and Women's Hospital · collab Hoffmann-La Roche · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out what effects (good and bad) taking capecitabine for 12 weeks before surgery will have on women with breast cancer.

Timeline

Start: 2004-09
Primary completion: 2007-09
Completion: —

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual”

Publications

Results Tolaney SM, Jeong J, Guo H, Brock J, Morganstern D, Come SE, Golshan M, Bellon J, Winer EP, Krop IE. A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer. Cancer Med. 2014 Apr;3(2):293-9. doi: 10.1002/cam4.164. Epub 2014 Jan 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	2000 mg/m2	Oral